Japan’s Senju Pharmaceutical has announced that Avarept ophthalmic suspension 0.3% (motugivatrep), discovered and licensed by ...

Neok Biotech’s $75 million series A venture round, which took the California-based biotech out of stealth mode, was not the ...

Japanese pharma major Shionogi announced the conclusion of a joint research and development agreement and investment ...

French pharma major Sanofi (Euronext: SAN) has received a Complete Response Letter (CRL) from the US regulator for ...

German biosimilars specialist Formycon (FWB: FYB) has won US approval for Nufymco (ranibizumab), an interchangeable ...

Artificial intelligence remains the most impactful technology shaping the pharmaceutical industry, with companies ...

French pharma major Sanofi today revealed it has agreed to acquire Dynavax Technologies, a US vaccines company with a ...

China’s rise as a biopharma innovator is reshaping global drug development, underpinned by regulatory reform and a rapidly ...

US rare disease specialist Agios Pharmaceuticals (Nasdaq: AGIO) has won approval for Aqvesme (mitapivat) to treat anemia in adults with alpha- or beta-thalassaemia, covering both ...

Australian regulator the Therapeutic Goods Administration (TGA) has received an internationally recognized designation from the World Health Organization (WHO), reaffirming TGA’s role as a trusted ...

The US Food and Drug Administration (FDA) has approved Accrufer (ferric maltol) capsules to treat pediatric patients ages 10 and older with iron deficiency.

The year 2025 was a major milestone in the history of rare disease drug development. After decades of slow but steady progress, many long-anticipated drugs were finally approved by regulatory agencies ...